The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Allakos Inc | COM | 01671P100 | 18,100 | 446,905 | SH | SOLE | 446,905 | 0 | 0 | ||
| Aravive Inc | COM | 03890D108 | 3,117 | 442,733 | SH | SOLE | 442,733 | 0 | 0 | ||
| Catabasis Pharmaceuticals Inc | COM | 14875P206 | 2,376 | 300,000 | SH | SOLE | 300,000 | 0 | 0 | ||
| Evelo Biosciences Inc | COM | 299734103 | 1,820 | 227,529 | SH | SOLE | 227,529 | 0 | 0 | ||
| Gossamer Bio Inc | COM | 38341P102 | 11,548 | 532,920 | SH | SOLE | 532,920 | 0 | 0 | ||
| Intercept Pharmaceuticals Inc | COM | 45845P108 | 23,595 | 210,937 | SH | SOLE | 210,937 | 0 | 0 | ||
| KalVista Pharmaceuticals Inc | COM | 483497103 | 3,391 | 118,500 | SH | SOLE | 118,500 | 0 | 0 | ||
| Liquidia Technologies Inc | COM | 53635D202 | 7,275 | 639,290 | SH | SOLE | 639,290 | 0 | 0 | ||
| Millendo Therapeutics Inc | COM | 60040X103 | 677 | 45,101 | SH | SOLE | 45,101 | 0 | 0 | ||
| Odonate Therapeutics Inc | COM | 676079106 | 13,174 | 595,850 | SH | SOLE | 595,850 | 0 | 0 | ||
| PDS Biotechnology Corp | COM | 70465T107 | 68 | 9,166 | SH | SOLE | 9,166 | 0 | 0 | ||
| Principia Biopharma Inc | COM | 74257L108 | 13,038 | 383,480 | SH | SOLE | 383,480 | 0 | 0 | ||
| Sunesis Pharmaceuticals Inc | COM | 867328700 | 4,556 | 3,750,000 | SH | SOLE | 3,750,000 | 0 | 0 | ||
| Surface Oncology Inc | COM | 86877M209 | 373 | 78,300 | SH | SOLE | 78,300 | 0 | 0 | ||
| Sutro BioPharma Inc | COM | 869367102 | 12,820 | 1,125,579 | SH | SOLE | 1,125,579 | 0 | 0 | ||
| Syros Pharmaceuticals Inc | COM | 87184Q107 | 9,688 | 1,059,938 | SH | SOLE | 1,059,938 | 0 | 0 | ||
| Trillium Therapeutics Inc | COM | 89620X506 | 47 | 71,619 | SH | SOLE | 71,619 | 0 | 0 | ||
| Urovant Sciences Ltd | COM | G9381B108 | 1,583 | 157,480 | SH | SOLE | 157,480 | 0 | 0 | ||